English 
Español 
français 
العربية Search
Search
Rapastinel (GLYX-13) is used as a pharmaceutical intermediate. Rapastinel is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at the glycine site of the NMDA receptor complex (Emax ≈ 25%).The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to both inhibit and enhance NMDA receptor-mediated signal transduction.
| Items | Specifications | Results |
| Appearance | White or almost white fluffy powder | Conforms |
| Solubility | Soluble in water and acetic acid | Conforms |
| Water content | ≤8.0% | 2.5% |
| Peptide purity | ≥98.0% | 99.5% |
| Product parameters | |
| Cas number: | 117928-94-6 |
| Appearance: | White or almost white fluffy powder |
| Purity: | 98%min |
| Package details: | 1g/vial; 10g/PE bottle |
| Brand: | Fortunachem |
Used as a peptide intermediate.
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
